Teva To Pay $35M In Suit Over Delayed Generic Inhalers
By Hailey Konnath · October 27, 2025, 9:05 PM EDT
Teva Pharmaceuticals will pay $35 million to resolve claims from a coalition of union healthcare funds that say the company schemed to delay generic competition for its QVAR asthma inhalers, according...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login